Sumitomo Pharma Co., Ltd. has withdrawn the registration for new share issuance, completing a fundraising total of approximately 41.58 billion yen. Going forward, a third-party allotment of up to 7,695,600 shares is planned.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-04-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4506-20260427-01.pdf","jir_short_summary":"Sumitomo Pharma Co., Ltd. has withdrawn the registration for new share issuance, completing a fundraising total of approximately 41.58 billion yen. Going forward, a third-party allotment of up to 7,695,600 shares is planned.","jir_summary":"### Regarding the Withdrawal of Registration\nSumitomo Pharma Co., Ltd. withdrew the registration for new share issuance submitted on March 2, 2026, on April 27, 2026. This was due to the completion of the planned new share offering. The securities offered were common shares of the company, with an issuance period from March 10, 2026, to March 9, 2027, and a fundraising cap set at 140 billion yen. The actual total issuance amount was 41,582,735,152 yen, and fundraising activities in overseas markets have also been completed.\n\n### Future Share Issuance Plans\nIn relation to an over-allotment offering, a third-party allotment of common shares is planned, allotted to SMBC Nikko Securities Inc., with up to 7,695,600 shares potentially issued on May 26, 2026. For details, please refer to the separately disclosed materials dated April 8 and April 20, 2026.","jir_financial_highlights":"Total Issuance Amount: 41,582,735,152 yen (Unknown)\nPlanned Fundraising Amount: Up to 140 billion yen (Unknown)\nMaximum Number of Shares for Third-Party Allotment: 7,695,600 shares (Unknown)","jir_category":"","jir_hashtags":"#SumitomoPharmaCoLtd, #CapitalPolicy, #NewShareIssuance","jir_key_figures":"Total Issuance Amount: 41,582,735,152 yen (Fundraising achieved)\nPlanned Fundraising Amount: Up to 140 billion yen (Registration limit)\nMaximum Number of Shares for Third-Party Allotment: 7,695,600 shares (Scheduled issuance on May 26, 2026)","jir_meta_title":"\u3010Sumitomo Pharma\u3011Withdrawal of New Share Issuance Registration and Scheduled Third-Party Allotment\uff5cApril 2026","jir_meta_description":"Sumitomo Pharma Co., Ltd. has withdrawn the registration for new share issuance, completing fundraising of approximately 41.58 billion yen. A third-party allotment of up to 7,695,600 shares is planned in May 2026.","jir_og_title":"\u3010Sumitomo Pharma\u3011Withdrawal of New Share Issuance Registration and Scheduled Third-Party Allotment\uff5cApril 2026","jir_og_description":"Sumitomo Pharma has withdrawn the registration for new share issuance, completing fundraising of approximately 41.58 billion yen. A third-party allotment of up to 7,695,600 shares is scheduled for May.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-42596","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n